Frequently Asked Questions As of July 2026, retatrutide has completed four Phase 3 readouts: TRIUMPH-4 (28.7% weight loss in knee OA population, December 2025), TRIUMPH-1 (28.3% weight loss in 2,339 general obesity patients, May 2026), TRANSCEND-T2D-1 (-2.0% HbA1c and 16.8% weight loss in 537 T2D patients, June 2026), and the TRIUMPH-1 sleep apnea substudy (60.6% AHI reduction, June 2026)
The appetite suppression helps manage hormonal hunger fluctuations common during perimenopause
Because the FDA does not regulate weight loss patches, people should speak with a doctor before using any of these products
Alternate between the abdomen, thighs, and arms to allow healing time
Bone microstructure and metabolism changes under the combined intervention of ketogenic diet with intermittent fasting: an in vivo study of rats
Retatrutide is ideal for studies seeking to understand multi-hormonal control of satiety, insulin secretion, and energy usage